| Literature DB >> 36148385 |
Trine Karlsen1,2, Morten Engstrøm3,4, Sigurd L Steinshamn5,6.
Abstract
Objective: Report on long-term follow-up results in the apnoea hypopnea index (AHI) and self-reported daytime sleepiness in participants with moderate to severe obstructive sleep apnoea at 12 weeks after completion of a high-intensity exercise training or control intervention.Entities:
Keywords: aerobic fitness; exercise; sleep
Year: 2022 PMID: 36148385 PMCID: PMC9486338 DOI: 10.1136/bmjsem-2022-001366
Source DB: PubMed Journal: BMJ Open Sport Exerc Med ISSN: 2055-7647
Figure 1Study flowchart. CON, control group; HIIT, high intensity interval training group, VO2max, maximal oxygen uptake.
Demographics of the participants at baseline
| Variable | HIIT (n=12) | CON (n=14) |
| Gender (women/men) | 3/9 | 3/11 |
| Age (years) | 53.5 (49.3–57.7) | 50.6 (45.1–56.2) |
| BMI (kg·m2) | 37.2 (33.8–40.5) | 37.5 (34.7–40.4) |
| Sleep apnoea duration (months) | 50 (18–83) | 86 (48–124) |
| CPAP users (n) | 10 | 12 |
| Systolic blood pressure (mm Hg) | 134 (122–145) | 137 (129–145) |
| Diastolic blood pressure (mm Hg) | 81 (72–90) | 83 (77–88) |
| Hb (g·dL−1) | 14.7 (14.1–15.2) | 14.9 (14.0–15.8) |
| HCT (%) | 43.5 (41.7–45.4) | 43.3 (40.9–45.7) |
| Total cholesterol (mmol·L−1) | 5.25 (4.55–5.94) | 5.24 (4.51–5.96) |
| LDL cholesterol (mmol·L−1) | 3.30 (2.67–3.93) | 3.29 (2.63–3.95) |
| HDL cholesterol (mmol·L−1) | 1.23 (1.06–1.40) | 1.07 (0.87–1.28) |
| Triglycerides (mmol·L−1) | 1.58 (1.15–2.02) | 1.95 (1.29–2.61) |
| CRP (Mg·L−1) | 6.16 (4.82–7.52) | 8.50 (4.25–12.75) |
| TSH (mU·L−1) | 1.83 (1.38–2.28) | 2.27 (1.79–2.76) |
| T4 (pmol·L−1) | 15.32 (14.30–16.33) | 15.27 (14.12–16.42) |
| HBA1c (%) | 5.75 (5.52–5.98) | 5.93 (5.57–6.29) |
| Insulin (pmol·L−1) | 113.5 (68.0–159.0) | 141.9 (29.9–153.9) |
| Leptin (pmol·L−1) | 1440 (778–2102) | 1656 (809–2504) |
Data are reported in mean and 95% confidence interval (95% CI).
BMI, body mass index; CON, control group; CPAP, continuous positive airway pressure; CRP, C reactive protein; Hb, haemoglobin; HBA1c, glycolyzed haemoglobin A1c; HCT, haematocrit; HDL, high-density lipoprotein; HIIT, high-intensity interval training; LDL, low-density lipoprotein; T4, thyroxin; TSH, thyroid-stimulating hormone.
Sleep evaluation
| Variable | HIIT (n=12) | CON (n=14) | ||||
| Baseline | 12 weeks | 24 weeks | Baseline | 12 weeks | 24 weeks | |
| AHI (events · h−1) | 32.3 (18.1–46.6) | 25.6 (12.7–38.5) | 30.7 (17.2–44.1) | 47.4 (33.7–61.2) | 45.5 (29.9–61.1) | 38.7 (22.8–54.5) |
| Epworth score | 9.9 (7.5–12.3) | 7.4 (5.0–9.9) | 7.0 (4.7–9.3) | 5.3 (3.1–7.5) | 5.8 (3.4–8.2) | 5.5 (3.9–7.0) |
| O2-saturation (%) | 92.5 (91.5–93.5) | 92.4 (91.4-93-4) | 93.2 (92.5–93.9) | 91.9 (91.2–92.7) | 92.2 (91.5–93.0) | 92.0 (91.1–92.8) |
| O2-desaturation events (n·h−1) | 35.1 (23.5–46.6) | 30.8 (16.0–45.5) | 32.9 (20.4–45.4) | 52.5 (36.3–68.8) | 47.6 (32.7–62.5) | 44.3 (27.3–61.3) |
Data are reported in mean and 95% CI. n=number of participants.
AHI, apnoea-hypopnoea index; O2, oxygen.
Maximal oxygen uptake and self-reported physical activity
| Variable | HIIT (n=9) | CON (n=7) | ||||
| Baseline | 12 weeks | 24 weeks | Baseline | 12 weeks | 24 weeks | |
| VO2max (L/min) | 3.05 (2.71–3.31) | 3.28 (2.97–3.60) | 3.19 (2.84–3.55) | 3.38 (2.84–3.90) | 3.54 (3.07–3.80) | 3.33 (2.87–3.82) |
| VO2max (mL/kg/min) | 25.6 (21.8–29.7) | 27.7 (23.6–32.5) | 27.2 (22.9–32.2) | 26.6 (20.8–33.2) | 27.1 (23.6–30.9) | 25.9 (21.3–30.1) |
|
|
| |||||
|
|
|
|
|
|
| |
| Total MET-min/ week | 3641 (595–6686) | 2697 (1561–3833) | 2501 (288–4714) | 2857 (0–5980) | 1991 (773–3210) | 3034 (1967–4100) |
| Walking (min/week) | 346 (0–708) | 162 (52-272) | 116 (18-214) | 230 (0–446) | 167 (45-290) | 191 (16-366) |
| Moderate (min/week) | 158 (0–351) | 262 (66-458) | 129 (2-257) | 148 (25-271) | 132 (12-252) | 189 (94-284) |
| Vigorous (min/week) | 120 (0–264) | 146 (71-223) | 131 (0–266) | 188 (0–436) | 91 (7–175) | 168 (52–284) |
Data are reported in mean and 95% CI.
CON, control; HIIT, high-intensity interval training; VO2max, maximal oxygen uptake.